This study is being conducted to evaluate the effectiveness and safety of starting a treatment called inclisiran early during a hospital stay for patients experiencing acute coronary syndrome. This term refers to a range of sudden medical conditions, such as a ST-elevation myocardial infarction or a non-ST-elevation myocardial infarction, which are commonly known as different types of heart attacks. The research focuses on how this medication works alongside standard care to lower LDL-C, which is often called “bad cholesterol.”

During the study, participants may receive inclisiran via a subcutaneous injection, which is a needle shot just under the skin, or a placebo. In addition to the study medication, participants will continue to take background treatments, which include medications like rosuvastatin or atorvastatin. These are types of statins used to manage cholesterol levels. The study will monitor various changes in blood levels, including PCSK9, apoB, VLDL, and triglycerides, to understand how the treatment affects the body over time.

The course of the study involves monitoring participants from the time they are in the hospital through a period of 150 days. Medical professionals will observe how the different treatments influence cholesterol levels and check for any side effects that may occur during the treatment period.